Although it is reasonable to withhold ARBs/BP lowering drugs during the acute period post-stroke, it may be appropriate and even advantageous to incorporate the novel, direct acting AT2 receptor agonist C21, as “bridge therapy,” until antihypertensive therapy initiation/re-initiation. Here, AGTR2 is linked to stroke disorder.